# DiaMedica Therapeutics Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/DiaMedica Therapeutics Inc.).

## Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, for preeclampsia and acute ischemic stroke. The company also has an earlier-stage preclinical program, DM300, for severe acute pancreatitis, but its business is centered on advancing DM199 through clinical trials and regulatory review.

## Products & services

• DM199 (rinvecalinase alfa) for preeclampsia
• DM199 for acute ischemic stroke
• Clinical development of recombinant KLK1 therapies
• Preclinical DM300 program for severe acute pancreatitis

- **DM199 clinical programs** (100%) — Lead recombinant KLK1 candidate being developed for preeclampsia and acute ischemic stroke.
- **Preclinical pipeline** (0%) — Early-stage DM300 program targeting severe acute pancreatitis.

- DM199 (rinvecalinase alfa) for preeclampsia
- DM199 for acute ischemic stroke
- Clinical development of recombinant KLK1 therapies
- Preclinical DM300 program for severe acute pancreatitis

## Customers

DiaMedica does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites, regulators, and potential development partners. If DM199 is approved, the end customers would be hospitals, physicians, and patients in maternal health and stroke care, with commercialization likely depending on a partner or licensing arrangement.

- **Clinical trial investigators and sites** (primary) — Run the preeclampsia and AIS studies and generate the data needed for regulatory advancement.
- **Regulatory agencies** (primary) — FDA and other agencies review pre-IND, IND, and clinical data before approval can progress.
- **Strategic partners and licensors** (secondary) — May provide funding, development support, or commercialization rights for DM199.
- **Future hospitals and physicians** (emerging) — Would use DM199 if approved for preeclampsia or acute ischemic stroke treatment.

- Clinical trial sites enrolling preeclampsia and stroke patients
- Regulators such as the FDA reviewing IND and trial data
- Potential pharma partners for licensing or co-development
- Future hospitals and physicians if DM199 reaches market

## Geography

The company is U.S.-based and its current business is primarily driven by clinical development and regulatory activity rather than product sales. Its ReMEDy2 stroke trial is described as global in scope, and the company is expanding its preeclampsia program through FDA interaction in the United States. Because it has no product revenue, geography mainly affects where trials are run, where regulators are engaged, and where future commercialization could occur.

- Headquartered in the United States
- FDA interaction is central to the preeclampsia program
- ReMEDy2 stroke trial is being expanded globally
- No product revenue disclosed by country
- Future commercialization geography is not yet defined

## Strategy

DiaMedica's strategy is to advance DM199 through clinical proof-of-concept and later-stage trials in preeclampsia and acute ischemic stroke. The company is also working to preserve flexibility through partnerships or licensing, since commercialization would require substantial capital and operational scale.

- **Advance DM199 in preeclampsia** (short-term) — Preeclampsia is a new indication with potential clinical differentiation and value creation.
- **Continue and expand ReMEDy2 in AIS** (short-term) — Stroke remains the core clinical program and a key path to eventual approval.
- **Preserve financing flexibility** (short-term) — The company has no product revenue and depends on external capital to fund R&D.
- **Build optionality for commercialization** (medium-term) — If DM199 succeeds, the company may need a partner to support sales, manufacturing, and distribution.

- Advance DM199 through clinical trials in PE and AIS
- Use FDA feedback to de-risk the preeclampsia program
- Expand the ReMEDy2 trial globally to broaden evidence
- Seek strategic partners or licensing to fund commercialization

## Risks

DiaMedica is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, and financing dependence. Its lead asset must reproduce early signals in later studies, and the company may need to raise capital before any product revenue is available. Government agency staffing or funding disruptions could also slow FDA review and other approvals that the business depends on.

- **Clinical trial failure or non-replication of data** [high] — DM199 must show consistent efficacy and safety in later trials to support approval.
- **Regulatory delay or adverse FDA feedback** [high] — The company depends on FDA review to advance from pre-IND/IND into later development.
- **Financing and dilution risk** [high] — The company has no product sales and relies on equity or other external funding.
- **Commercialization execution risk** [medium] — If approved, DiaMedica may need partners or significant internal buildout for launch.
- **Government agency disruption** [medium] — Reduced staffing or funding at FDA/SEC can delay approvals and normal oversight functions.

- Clinical results may not replicate earlier promising data
- FDA or other agency delays can slow development and approval
- No product revenue until regulatory approval is achieved
- Future funding needs may force dilution or unfavorable licensing
- Commercialization would require major spend on sales and manufacturing

## Accounting

As a clinical-stage biotech, DiaMedica's reported results are dominated by R&D expense, stock-based compensation, and cash investment balances rather than revenue recognition. Investors should watch how trial expansion, manufacturing development, and headcount changes flow through operating expenses, as well as how marketable securities affect other income and liquidity. The company also has no product revenue, so any future milestone, licensing, or royalty accounting would be highly material.

- **Research and development expense recognition** — Higher R&D spend can materially increase quarterly cash burn.
- **Stock-based compensation** — Affects reported operating expense and dilution analysis.
- **Marketable securities and interest income** — Changes in balances and rates affect non-operating results and liquidity.
- **Future collaboration or licensing accounting** — Could introduce revenue recognition judgments once commercialization partnerships exist.

- R&D expense reflects trial expansion, manufacturing work, and clinical staffing
- G&A includes stock-based compensation, insurance, rent, legal, and patent costs
- Interest income on marketable securities drives other income, net
- No product revenue yet, so future licensing or milestone accounting would matter
- Cash and marketable securities levels are key to runway assessment

---

*Last updated: 2026-04-28T20:01:46.885098+00:00*